(function(){var loadHandler=window['sl_{70F84434-E230-4897-A900-6C791B0E8453}'];loadHandler&&loadHandler(1, '<div id="spr0_52e6c6b3"><div id="spr1_52e6c6b3" class="kern slide"><img id="img4_52e6c6b3" src="data/img1.png" width="720px" height="540px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_52e6c6b3" class="kern slide"><img id="img0_52e6c6b3" src="data/img2.png" width="721.48" height="100.8" alt="" style="left:-1.48px;"/><div id="svg1_52e6c6b3" style="left:-1.48px;top:99.523px;"><svg width="722" height="4" viewBox="0 0 722 4"><path fill="#c76c02" d="M0,0 h721.48 v3.6 h-721.48 Z"/></svg></div><div id="svg2_52e6c6b3" style="left:-1.48px;top:0.523px;"><svg width="722" height="4" viewBox="0 0 722 4"><path fill="#2e3546" d="M0,0 h721.48 v3.6 h-721.48 Z"/></svg></div><img id="img1_52e6c6b3" src="data/img3.png" width="721.48" height="43.101" alt="" style="top:496.899px;"/><div id="spr3_52e6c6b3" style="left:657.715px;top:499.855px;"><img id="img2_52e6c6b3" src="data/img4.png" width="56" height="36" alt="CHRC logo_with text.psd" style="left:-0.105px;top:-0.177px;"/></div><div id="spr4_52e6c6b3" style="left:0px;top:23.347px;"><div style="width:0px;"><span id="txt0_52e6c6b3" data-width="644.501953" style="left:38.41px;top:5.272px;">Non-Statin Therapy for Adjunct LDL-Lowering</span></div></div><div id="spr5_52e6c6b3" style="left:6.496px;top:495.353px;"><div style="width:0px;"><span id="txt1_52e6c6b3" class="nokern" data-width="245.074219" style="left:7.2px;top:4.041px;">* Effects on other lipoproteins not listed for brevity. † Cholesterol Absorption Inhibitor</span></div><div style="width:0px;"><span id="txt2_52e6c6b3" class="nokern relpos" data-width="5.472656" style="left:7.2px;top:13.641px;">a.</span><span id="txt3_52e6c6b3" class="nokern relpos" data-width="144.796875" style="left:19.727px;top:13.641px;">Jacobson TA, et al. J Clin Lipidol 2014;8:473-488;</span></div><div style="width:0px;"><span id="txt4_52e6c6b3" class="nokern relpos" data-width="5.472656" style="left:7.2px;top:23.241px;">b.</span><span id="txt5_52e6c6b3" class="nokern relpos" data-width="162.277344" style="left:19.727px;top:23.241px;">Rosenson RS, et al. J Am Coll Cardiol.2018;72:314-329</span></div><div style="width:0px;"><span id="txt6_52e6c6b3" class="nokern relpos" data-width="5.105469" style="left:7.2px;top:32.841px;">c.</span><span id="txt7_52e6c6b3" class="nokern relpos" data-width="152.808594" style="left:20.095px;top:32.841px;">Salami JA, et al. J Am Heart Assoc. 2018;7:e007132</span></div></div><div id="spr6_52e6c6b3" style="left:59.196px;top:128.407px;"><img id="img3_52e6c6b3" src="data/img5.png" width="345" height="347" alt="" style="left:0.041px;top:-0.146px;"/></div><div id="svg4_52e6c6b3" style="left:432.212px;top:142.538px;"><svg width="271" height="313" viewBox="0 0 271 313"><path fill="#525f83" fill-opacity="0.2" d="M0,0 h270.393 v312.623 h-270.393 Z"/></svg></div><div id="spr7_52e6c6b3" style="left:432.212px;top:142.538px;"><div style="width:0px;"><span id="txt8_52e6c6b3" class="nokern relpos" style="left:7.2px;top:6.517px;"></span><span id="txt9_52e6c6b3" class="relpos" data-width="218.285156" style="left:21.465px;top:6.103px;">Increasing trend in non-statin use</span></div><div style="width:0px;"><span id="txt10_52e6c6b3" data-width="219.076172" style="left:29.7px;top:27.703px;">among adults with atherosclerotic</span></div><div style="width:0px;"><span id="txt11_52e6c6b3" class="relpos" data-width="31.148438" style="left:29.7px;top:49.303px;">CVD</span><span id="txt12_52e6c6b3" class="relpos" data-width="11.472656" style="left:29.695px;top:49.435px;">(c)</span></div><div style="width:0px;"><span id="txt13_52e6c6b3" class="nokern relpos" style="left:43.2px;top:70.793px;">─</span><span id="txt14_52e6c6b3" class="relpos" data-width="156.843750" style="left:54.013px;top:70.793px;">1 in 7 adults use non-statin</span></div><div style="width:0px;"><span id="txt15_52e6c6b3" data-width="183.812500" style="left:65.7px;top:89.993px;">therapy, including high-intensity</span></div><div style="width:0px;"><span id="txt16_52e6c6b3" data-width="67.101563" style="left:65.7px;top:109.193px;">statin users</span></div><div style="width:0px;"><span id="txt17_52e6c6b3" class="nokern relpos" style="left:43.2px;top:128.393px;">─</span><span id="txt18_52e6c6b3" class="relpos" data-width="156.070313" style="left:54.013px;top:128.393px;">Prescriptions for non-statin</span></div><div style="width:0px;"><span id="txt19_52e6c6b3" data-width="171.414063" style="left:65.7px;top:147.593px;">therapy doubled from 7.5% in</span></div><div style="width:0px;"><span id="txt20_52e6c6b3" data-width="131.328125" style="left:65.7px;top:166.793px;">2002 to 13.9% in 2013</span></div><div style="width:0px;"><span id="txt21_52e6c6b3" class="nokern relpos" style="left:7.2px;top:205.717px;"></span><span id="txt22_52e6c6b3" class="relpos" data-width="221.519531" style="left:21.465px;top:205.303px;">Primarily used as an adjunct LDL-</span></div><div style="width:0px;"><span id="txt23_52e6c6b3" data-width="207.588867" style="left:29.7px;top:226.904px;">lowering therapy in combination</span></div><div style="width:0px;"><span id="txt24_52e6c6b3" class="relpos" data-width="73.019531" style="left:29.7px;top:248.503px;">with statins</span><span id="txt25_52e6c6b3" class="relpos" data-width="11.472656" style="left:29.695px;top:248.635px;">(c)</span></div><div style="width:0px;"><span id="txt26_52e6c6b3" class="nokern relpos" style="left:43.2px;top:269.993px;">─</span><span id="txt27_52e6c6b3" class="relpos" data-width="196.203125" style="left:54.013px;top:269.993px;">Not used as much in patients with</span></div><div style="width:0px;"><span id="txt28_52e6c6b3" data-width="99.203125" style="left:65.7px;top:289.193px;">statin intolerance</span></div></div><div id="spr8_52e6c6b3" style="left:17.395px;top:128.407px;"><div style="width:0px;"><span id="txt29_52e6c6b3" data-width="228.859375" style="left:7.943px;top:285.57px;">Non-Statin Therapy Effect on LDL-C*</span></div></div></div></div>');})();